We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has been focusing its attention on proposed risk evaluation and mitigation strategies (REMS) for Amgen’s pending applications for Nplate and Enbrel.